{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:28:45Z","timestamp":1788834525644,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s13555-024-01229-6","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T04:01:31Z","timestamp":1722225691000},"page":"2607-2620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct02694523","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03047395","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02207224","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02576431","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03482011","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03556202","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Chang-Yu","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Li-Tien","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-1474","authenticated-orcid":false,"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"1229_CR1","doi-asserted-by":"publisher","first-page":"12849","DOI":"10.3390\/IJMS232112849","volume":"23","author":"F Bellinato","year":"2022","unstructured":"Bellinato F, Chiricozzi A, Piaserico S, Targher G, Gisondi P. Could targeted pharmacotherapies exert a \u201cdisease modification effect\u201d in patients with chronic plaque psoriasis? Int J Mol Sci. 2022;23:12849. https:\/\/doi.org\/10.3390\/IJMS232112849.","journal-title":"Int J Mol Sci"},{"key":"1229_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","volume":"156","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156:649\u201358. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0723.","journal-title":"JAMA Dermatol"},{"key":"1229_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2022.100116","volume":"2","author":"D Tian","year":"2022","unstructured":"Tian D, Lai Y. The relapse of psoriasis: mechanisms and mysteries. JID Innov. 2022;2: 100116. https:\/\/doi.org\/10.1016\/j.xjidi.2022.100116.","journal-title":"JID Innov"},{"key":"1229_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40257-022-00679-y","volume":"23","author":"M Masson Regnault","year":"2022","unstructured":"Masson Regnault M, Shourick J, Jendoubi F, Tauber M, Paul C. Time to relapse after discontinuing systemic treatment for psoriasis: a systematic review. Am J Clin Dermatol. 2022;23:433\u201347. https:\/\/doi.org\/10.1007\/s40257-022-00679-y.","journal-title":"Am J Clin Dermatol"},{"key":"1229_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/DS.DS-D-22-00096","volume":"41","author":"L Silocchi","year":"2023","unstructured":"Silocchi L, Damiani G. Dermatological management in special population affected by psoriasis: a case report of an amputated transgender with psoriasis treated with apremilast. Dermatol Sin. 2023;41:38\u20139. https:\/\/doi.org\/10.4103\/DS.DS-D-22-00096.","journal-title":"Dermatol Sin"},{"key":"1229_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/S13555-023-01064-1\/TABLES\/3","volume":"14","author":"Y Tada","year":"2024","unstructured":"Tada Y, Soliman AM, Ishii K, Sakuma R, Puig L, Davis M, et al. Real-world discontinuation and switching patterns for interleukin-inhibitor treatments in patients with moderate-to-severe psoriasis in Japan. Dermatol Ther (Heidelb). 2024;14:99\u2013114. https:\/\/doi.org\/10.1007\/S13555-023-01064-1\/TABLES\/3.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1229_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15052","volume":"34","author":"W Owczarek","year":"2021","unstructured":"Owczarek W, Dzik M, Narbutt J, Walecka I, Kowalczyk M. Real-world evidence on time to relapse of plaque psoriasis after discontinuation of biologic treatment in Poland. Dermatol Ther (Heidelb). 2021;34: e15052. https:\/\/doi.org\/10.1111\/dth.15052.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1229_CR8","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1111\/JDV.16809","volume":"35","author":"R Rivera","year":"2021","unstructured":"Rivera R, Martorell A, L\u00f3pez A, Salgado L, Sahuquillo A, de la Cueva P, et al. Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study. J Eur Acad. 2021;35:e65\u20137. https:\/\/doi.org\/10.1111\/jdv.16809.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1229_CR9","first-page":"412","volume":"151","author":"Y-C Tsai","year":"2016","unstructured":"Tsai Y-C, Tsai T-F. A review of clinical trials of biologic agents and small molecules for psoriasis in Asian subjects. G Ital Dermatol Venereol. 2016;151:412\u201331.","journal-title":"G Ital Dermatol Venereol"},{"key":"1229_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/157339709789208615","volume":"5","author":"T-F Tsai","year":"2009","unstructured":"Tsai T-F, Yeh T-Y. The use of biologics for psoriasis in Asia-Pacific Region. Curr Rheumatol Rev. 2009;5:149\u201352. https:\/\/doi.org\/10.2174\/157339709789208615.","journal-title":"Curr Rheumatol Rev"},{"key":"1229_CR11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/1346-8138.15109","volume":"46","author":"K Reich","year":"2019","unstructured":"Reich K, Song M, Li S, Jiang J, Youn SW, Tsai TF, et al. Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. J Dermatol. 2019;46:1141\u201352. https:\/\/doi.org\/10.1111\/1346-8138.15109.","journal-title":"J Dermatol"},{"key":"1229_CR12","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/1346-8138.15004","volume":"46","author":"MG Lee","year":"2019","unstructured":"Lee MG, Huang YH, Lee JH, Lee SC, Kim TG, Aw DCW, et al. Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: subgroup analysis from the CLEAR study. J Dermatol. 2019;46:752\u20138. https:\/\/doi.org\/10.1111\/1346-8138.15004.","journal-title":"J Dermatol"},{"key":"1229_CR13","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","volume":"73","author":"D Tha\u00e7i","year":"2015","unstructured":"Tha\u00e7i D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2015.05.013.","journal-title":"J Am Acad Dermatol"},{"key":"1229_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/PTT.S101232","volume":"6","author":"RK Singh","year":"2016","unstructured":"Singh RK, Lee KM, Ucmak D, Brodsky M, Atanelov Z, Farahnik B, et al. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:93. https:\/\/doi.org\/10.2147\/PTT.S101232.","journal-title":"Psoriasis (Auckl)"},{"key":"1229_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/J.JAAD.2019.03.048","volume":"81","author":"A Egeberg","year":"2019","unstructured":"Egeberg A, Bryld LE, Skov L. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;81:173\u20138. https:\/\/doi.org\/10.1016\/J.JAAD.2019.03.048.","journal-title":"J Am Acad Dermatol"},{"key":"1229_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4103\/DS.DS_36_18","volume":"37","author":"TS Chiu","year":"2019","unstructured":"Chiu TS, Tsai TF. Treatment response in patients with moderate-to-severe psoriasis who had inadequate response to prior secukinumab. Dermatol Sin. 2019;37:129\u201333. https:\/\/doi.org\/10.4103\/DS.DS_36_18.","journal-title":"Dermatol Sin"},{"key":"1229_CR17","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/BJD.16252","volume":"178","author":"HJ Weng","year":"2018","unstructured":"Weng HJ, Wang TS, Tsai TF. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series. Br J Dermatol. 2018;178:1439\u201340. https:\/\/doi.org\/10.1111\/BJD.16252.","journal-title":"Br J Dermatol"},{"key":"1229_CR18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.4103\/DS.DS_45_21","volume":"39","author":"JP Chao","year":"2021","unstructured":"Chao JP, Tsai TF. Psoriasis flare following ChAdOx1-S\/nCoV-19 vaccination in patients with psoriasis under biologic treatment. Dermatol Sin. 2021;39:208\u20139. https:\/\/doi.org\/10.4103\/DS.DS_45_21.","journal-title":"Dermatol Sin"},{"key":"1229_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.812010","volume":"8","author":"YW Huang","year":"2021","unstructured":"Huang YW, Tsai TF. Exacerbation of psoriasis following COVID-19 vaccination: report from a single center. Front Med (Lausanne). 2021;8: 812010. https:\/\/doi.org\/10.3389\/fmed.2021.812010.","journal-title":"Front Med (Lausanne)"},{"key":"1229_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/DS.DS_11_22","volume":"40","author":"PT Lin","year":"2022","unstructured":"Lin PT, Chi CC. Erythrodermic psoriasis following ChAdOx1 nCOV-19 vaccination: a case report. Dermatol Sin. 2022;40:62\u20133. https:\/\/doi.org\/10.4103\/DS.DS_11_22.","journal-title":"Dermatol Sin"},{"key":"1229_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/DS.DS-D-23-00004","volume":"41","author":"YSO Hsu","year":"2023","unstructured":"Hsu YSO, Tsai TF. A case of new-onset palmoplantar pustulosis following mRNA COVID-19 vaccination. Dermatol Sin. 2023;41:127\u20138. https:\/\/doi.org\/10.4103\/DS.DS-D-23-00004.","journal-title":"Dermatol Sin"},{"key":"1229_CR22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/S13555-019-0310-5","volume":"9","author":"YW Huang","year":"2019","unstructured":"Huang YW, Tsai TF. Remission duration and long-term outcomes in patients with moderate-to-severe psoriasis treated by biologics or tofacitinib in controlled clinical trials: a 15-year single-center experience. Dermatol Ther (Heidelb). 2019;9:553\u201369. https:\/\/doi.org\/10.1007\/S13555-019-0310-5.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1229_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/J.JAAD.2019.01.035","volume":"88","author":"HY Chiu","year":"2023","unstructured":"Chiu HY, Hui RCY, Tsai TF, Chen YC, Chang Liao NF, Chen PH, et al. Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: an 8-year multicenter study. J Am Acad Dermatol. 2023;88:71\u20138. https:\/\/doi.org\/10.1016\/J.JAAD.2019.01.035.","journal-title":"J Am Acad Dermatol"},{"key":"1229_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad329","author":"M Lebwohl","year":"2023","unstructured":"Lebwohl M, Iversen L, Eidsmo L, Krueger JG, Su\u00e1rez-Fari\u00f1as M, Tomalin L, et al. Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies. Clin Exp Dermatol. 2023. https:\/\/doi.org\/10.1093\/ced\/llad329.","journal-title":"Clin Exp Dermatol"},{"key":"1229_CR25","unstructured":"Sch\u00e4kel et al. Treatment-free period of more than 1 year in guselkumab super responders with short disease duration of psoriasis: withdrawal data from the GUIDE trial. 2023 EADV Congress, Berlin: 2023."},{"key":"1229_CR26","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1001\/jamadermatol","volume":"88","author":"Y Luu","year":"2023","unstructured":"Luu Y, Cheng A-L, Reisz C. Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: a nationwide cohort study. J Am Acad Dermatol. 2023;88:1378\u201381. https:\/\/doi.org\/10.1001\/jamadermatol.","journal-title":"J Am Acad Dermatol"},{"key":"1229_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/DDG.15251","volume":"22","author":"L Mastorino","year":"2024","unstructured":"Mastorino L, Dapavo P, Susca S, Cariti C, Siliquini N, Verrone A, et al. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment. J Dtsch Dermatol Ges. 2024;22:34\u201342. https:\/\/doi.org\/10.1111\/DDG.15251.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1229_CR28","doi-asserted-by":"publisher","first-page":"1341708","DOI":"10.3389\/FIMMU.2023.1341708","volume":"11","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, Balato A, Bardazzi F, Burlando M, et al. Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses\u2014IL PSO (Italian landscape psoriasis). Front Immunol. 2024;11:1341708. https:\/\/doi.org\/10.3389\/FIMMU.2023.1341708.","journal-title":"Front Immunol"},{"key":"1229_CR29","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/17512433.2022.2103538","volume":"15","author":"C-P Yeh","year":"2022","unstructured":"Yeh C-P, Huang YW, Tsai T-F. Comparison of the relative efficacy of different biologics in different body areas in patients with moderate to severe psoriasis receiving biologics and tofacitinib in phase 3 randomized controlled trials: a 15-year single-center experience. Expert Rev Clin Pharmacol. 2022;15:887\u201395. https:\/\/doi.org\/10.1080\/17512433.2022.2103538.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1229_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.15214","volume":"35","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Real world practice indirect comparison between guselkumab and risankizumab: results from an Italian retrospective study. Dermatol Ther (Heidelb). 2022;35: e15214. https:\/\/doi.org\/10.1111\/DTH.15214.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1229_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/24755303221127338","volume":"7","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A. Resident memory T cells in psoriasis: key to a cure? J Psoriasis Psoriatic Arthritis. 2022;7:157\u20139. https:\/\/doi.org\/10.1177\/24755303221127338.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"1229_CR32","doi-asserted-by":"publisher","first-page":"11251","DOI":"10.3390\/IJERPH182111251","volume":"18","author":"M Kasprowicz-Furma\u0144czyk","year":"2021","unstructured":"Kasprowicz-Furma\u0144czyk M, Czerwi\u0144ska J, Placek W, Owczarczyk-Saczonek A. Assessment of the tissue resident memory cells in lesional skin of patients with psoriasis and in healthy skin of healthy volunteers. Int J Environ Res Public Health. 2021;18:11251. https:\/\/doi.org\/10.3390\/IJERPH182111251.","journal-title":"Int J Environ Res Public Health"},{"key":"1229_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/J.CRIMMU.2023.100067","volume":"4","author":"C Dong","year":"2023","unstructured":"Dong C, Lin L, Du J. Characteristics and sources of tissue-resident memory T cells in psoriasis relapse. Curr Res Immunol. 2023;4: 100067. https:\/\/doi.org\/10.1016\/J.CRIMMU.2023.100067.","journal-title":"Curr Res Immunol"},{"key":"1229_CR34","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/BJD.17748","volume":"181","author":"S Vo","year":"2019","unstructured":"Vo S, Watanabe R, Koguchi-Yoshioka H, Matsumura Y, Ishitsuka Y, Nakamura Y, et al. CD8 resident memory T cells with interleukin 17A-producing potential are accumulated in disease-na\u00efve nonlesional sites of psoriasis possibly in correlation with disease duration. Br J Dermatol. 2019;181:410\u20132. https:\/\/doi.org\/10.1111\/BJD.17748.","journal-title":"Br J Dermatol"},{"key":"1229_CR35","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/jdv.18846","volume":"37","author":"L Iversen","year":"2023","unstructured":"Iversen L, Conrad C, Eidsmo L, Costanzo A, Narbutt J, Pinter A, et al. Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study. J Eur Acad Dermatol Venereol. 2023;37:1004\u201316. https:\/\/doi.org\/10.1111\/jdv.18846.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1229_CR36","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/JDV.19236","volume":"37","author":"K Sch\u00e4kel","year":"2023","unstructured":"Sch\u00e4kel K, Reich K, Asadullah K, Pinter A, Jullien D, Weisenseel P, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 2023;37:2016\u201327. https:\/\/doi.org\/10.1111\/JDV.19236.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1229_CR37","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1016\/J.JID.2023.03.594","volume":"143","author":"J Angsana","year":"2023","unstructured":"Angsana J, Kohler K, Sendecki J, Leung MW, Tabori S, Kr\u00fcger N, et al. Higher IL-10+ T cell and treg cell counts in psoriatic skin are associated with super-response to guselkumab: data from the phase 3 guide trial. J Invest Dermatol. 2023;143:S101. https:\/\/doi.org\/10.1016\/J.JID.2023.03.594.","journal-title":"J Invest Dermatol"},{"key":"1229_CR38","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/S12325-022-02379-9","volume":"40","author":"C Lynde","year":"2023","unstructured":"Lynde C, Riedl E, Maul JT, Torres T, Pinter A, Fabbrocini G, et al. Comparative effectiveness of biologics across subgroups of patients with moderate-to-severe plaque psoriasis: results at week 12 from the PSoHO study in a real-world setting. Adv Ther. 2023;40:869\u201386. https:\/\/doi.org\/10.1007\/S12325-022-02379-9.","journal-title":"Adv Ther"},{"key":"1229_CR39","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/EXD.14810","volume":"32","author":"CY Hsieh","year":"2023","unstructured":"Hsieh CY, Tsai TF. Effectiveness and safety of reduced-dose secukinumab switching to risankizumab for psoriasis patients in Asian population: a case series. Exp Dermatol. 2023;32:1048\u201350. https:\/\/doi.org\/10.1111\/EXD.14810.","journal-title":"Exp Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01229-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01229-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01229-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T12:44:34Z","timestamp":1726145074000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01229-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01229-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chang-Yu Hsieh received honoraria for educational events from Boehringer Ingelheim. Francis Li-Tien Hsu has no conflict of interest. Tsen-Fang Tsai has conducted clinical trials or received honoraria for serving as a consultant for Abbvie, AnaptysBio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli-Lilly, Galderma, GSK, Janssen-Cilag, Leo Pharma, Merck Sharp & Dohme, Novartis International, Pfizer, PharmaEssentia, Sanofi, Sun Pharma, and UCB Pharma. Tsen-Fang Tsai is an Editorial Board member of Dermatology and Therapy. Tsen-Fang Tsai was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted with the approval of institutional review board from National Taiwan University Hospital (201904124RINC). All included patients provided written consent for data collection. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}